Bondy M L, Spitz M R, Halabi S, Fueger J J, Schantz S P, Sample D, Hsu T C
Department of Epidemiology, University of Texas M.D. Anderson Cancer Center, Houston 77030.
Cancer Epidemiol Biomarkers Prev. 1993 Mar-Apr;2(2):103-6.
This study evaluated the relationship between family history of cancer and bleomycin-induced mutagen sensitivity. The study included 108 patients who registered at The University of Texas M.D. Anderson Cancer Center from June 1987 to June 1991 with histologically confirmed and previously untreated squamous cell carcinoma of the upper aerodigestive tract. All patients underwent the mutagen sensitivity assay and completed a self-administered risk evaluation questionnaire, including a detailed family history. The patients reported having 650 first-degree relatives, including 54 cases with cancers. The patients were classified as mutagen sensitive (> or = 1 chromosome break/cell) or not mutagen sensitive (< or = 0.99 chromosome breaks/cell). Odds ratios (ORs) were calculated to test for significant associations between mutagen sensitivity and family history of cancer. We found a significant OR (OR = 2.63; 95% confidence interval = 1.06-6.53) for patients who were mutagen sensitive and had one first-degree relative affected with cancer. For mutagen-sensitive patients with two or more first-degree relatives affected with cancer, the OR increased to 6.59 (95% confidence interval = 1.69-25.72). Although 88% of the patients were ever smokers, cigarette smoking was not found to be related to mutagen sensitivity. The study findings suggest that patients who have defective DNA repair capability as evidenced by the mutagen sensitivity assay are significantly more likely to report a family history of cancer than patients who are not mutagen sensitive. Further studies are needed to confirm that mutagen-sensitive individuals have inherited an increased risk of cancer.
本研究评估了癌症家族史与博来霉素诱导的诱变敏感性之间的关系。该研究纳入了108例于1987年6月至1991年6月在德克萨斯大学MD安德森癌症中心登记的患者,这些患者经组织学确诊为上消化道鳞状细胞癌且此前未接受过治疗。所有患者均接受了诱变敏感性检测,并完成了一份自我管理的风险评估问卷,包括详细的家族史。患者报告有650名一级亲属,其中54例患有癌症。患者被分为诱变敏感(≥1条染色体断裂/细胞)或非诱变敏感(≤0.99条染色体断裂/细胞)。计算比值比(OR)以检验诱变敏感性与癌症家族史之间的显著关联。我们发现,对于诱变敏感且有一名患癌一级亲属的患者,OR值显著(OR = 2.63;95%置信区间 = 1.06 - 6.53)。对于有两名或更多患癌一级亲属的诱变敏感患者,OR值增至6.59(95%置信区间 = 1.69 - 25.72)。尽管88%的患者曾经吸烟,但未发现吸烟与诱变敏感性有关。研究结果表明,经诱变敏感性检测证明具有DNA修复能力缺陷的患者比非诱变敏感患者更有可能报告癌症家族史。需要进一步研究来证实诱变敏感个体是否遗传了增加的患癌风险。